The term mechanism of action refers to the specific biochemical interaction through which a drug substance produces its pharmacological effect. https://www.bharatbook.com/drugs-market-research-reports-792683/oncology-cancer-drugs-ranking-detailed-regulatory-approval-profiles.html
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.
Oncology (1985-2016) - 157 cancer drugs - Ranking and detailed regulatory approval profiles” is a comprehensive drug ranking and profiling report that ranks cancer drugs based on total approvals and unique approvals received in US, Europe and Japan. It provides the regulatory approval details of each drug for the past 30 years (1985-2016) in both the tabular and (an interesting) infographic formats. Additionally, the basic drug-specific information such as first approvals, breakthrough,
orphan designations, black box warnings, etc., is also
presented along with negative developments of drugs
recalled, discontinued and withdrawn.
Trade names: Drugs are often known by different brand names (trade names) in different geographies. For instance, Rituxan is the trade name for Rituximab in the US, whereas it is known as Mabthera in Europe. We have presented each drug’s trade name used in different geographies in our report.Companies involved in marketing: Drugs are often sold or
marketed in different geographies by different companies.
For instance, Aranesp is marketed in the US and Europe by
Amgen, whereas in Japan it is marketed by
Kyowa Hakko Kirin.
Active pharmaceutical ingredient: Active pharmaceutical ingredients (API) are the active ingredients in medications, carried by the excipient. In each case, the drug has an API and it has a trade name, by which it is known in the market. For instance, Revlimid is the brand or trade name, whereas lenalidomide is its API.Therapy segment: We have classified drugs into five
major therapy segments ‑ Targeted, Chemo, Hormone,
Vaccines and Adjuvants. For instance, Herceptin is a
Targeted Therapy drug whereas Zytiga is a Hormone
Immuno-oncology: This is a growing area of cancer therapy. We have highlighted whether the drugs classified fall under this category or not. For instance, Opdivo is an immuno-oncology drug.Class of drug: Various therapy segments are further classified into classes of drugs. Monoclonal antibodies, tyrosine kinase and alkylating agent are examples of classes of drugs. Yervoy is a monoclonal antibody whereas
Tarceva is a tyrosine kinase inhibitor.
Molecule type: Drugs are classified into two categories,
small and large, on the basis of their molecular weight;
greater than 900 daltons are large molecules and less than
900 daltons are small molecules. Large molecules are
also known as biological drugs.
Dosage form: We have explained whether the dosage is in
the form of vials/injections (injectable) or tablets/capsules
(oral). For instance, Tecentriq is an injectable drug whereas
Thalomid is an oral tablet.
Route of administration: We have explained whether the drug is taken orally or through the intravenous route. For instance, Empliciti (for multiple myeloma) is taken through the intravenous route.Mechanism of action: The term mechanism of action refers to the specific biochemical interaction through which a drug substance
produces its pharmacological effect. A mechanism of
action usually includes mention of the specific molecular
targets to which the drug binds, such as an enzyme
First approved indication in the geographies US, EU and Japan: Many cancer drugs are often approved for more than one indication. We have highlighted the first approved indication of each drug in the various geographies. For instance, Xeloda was first approved for metastatic breast cancer in the US and Japan whereas, in Europe,
it was first approved for colorectal cancer.
Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
LinkedIn :Bharat Book Bureau